These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 7853339

  • 1. Pimelautide or trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response.
    Déprez B, Gras-Masse H, Martinon F, Gomard E, Lévy JP, Tartar A.
    J Med Chem; 1995 Feb 03; 38(3):459-65. PubMed ID: 7853339
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS, Choi MJ, Kim TY, Cho SY, Cheong HS.
    Vaccine; 1999 Mar 17; 17(11-12):1540-8. PubMed ID: 10195791
    [Abstract] [Full Text] [Related]

  • 3. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ.
    Cell Immunol; 1995 Feb 17; 160(2):217-23. PubMed ID: 7720083
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo.
    Sauzet JP, Moog C, Krivine A, Martinon F, Bossus M, Gras-Masse H, Tartar A, Guillet JG, Gomard E.
    AIDS Res Hum Retroviruses; 1998 Jul 01; 14(10):901-9. PubMed ID: 9671219
    [Abstract] [Full Text] [Related]

  • 5. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 01; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 6. Synthesis of immunoadjuvant conjugates with HIV-derived peptide inducing peptide-specific antibody.
    Maruyama Y, Kurimura M, Achiwa K.
    Chem Pharm Bull (Tokyo); 1994 Aug 01; 42(8):1709-11. PubMed ID: 7954925
    [No Abstract] [Full Text] [Related]

  • 7. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ.
    J Immunol; 1997 Jan 15; 158(2):834-41. PubMed ID: 8993001
    [Abstract] [Full Text] [Related]

  • 8. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.
    Layton GT, Harris SJ, Gearing AJ, Hill-Perkins M, Cole JS, Griffiths JC, Burns NR, Kingsman AJ, Adams SE.
    J Immunol; 1993 Jul 15; 151(2):1097-107. PubMed ID: 8335892
    [Abstract] [Full Text] [Related]

  • 9. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 10. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans.
    Doe B, Steimer KS, Walker CM.
    Eur J Immunol; 1994 Oct 10; 24(10):2369-76. PubMed ID: 7523139
    [Abstract] [Full Text] [Related]

  • 11. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J, Boutillon C, Georges B, Ameisen JC, Tartar A, Auriault C.
    J Pept Sci; 1996 Oct 10; 2(3):165-75. PubMed ID: 9231325
    [Abstract] [Full Text] [Related]

  • 12. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R.
    J Virol; 2006 Feb 10; 80(3):1414-26. PubMed ID: 16415019
    [Abstract] [Full Text] [Related]

  • 13. Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response.
    Nehete PN, Arlinghaus RB, Sastry KJ.
    Viral Immunol; 1994 Feb 10; 7(4):189-97. PubMed ID: 7576033
    [Abstract] [Full Text] [Related]

  • 14. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant.
    Nardelli B, Defoort JP, Huang W, Tam JP.
    AIDS Res Hum Retroviruses; 1992 Aug 10; 8(8):1405-7. PubMed ID: 1466968
    [No Abstract] [Full Text] [Related]

  • 15. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM, Bond KB, Ruhadze ER, Olsen MR, Takayama K, Hunter RL.
    AIDS Res Hum Retroviruses; 1998 Nov 01; 14(16):1457-71. PubMed ID: 9824324
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.